Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $45.20 USD
Change Today +1.24 / 2.82%
Volume 1.5M
AKRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

akorn inc (AKRX) Snapshot

Open
$44.35
Previous Close
$43.96
Day High
$45.30
Day Low
$43.57
52 Week High
04/24/15 - $57.10
52 Week Low
06/2/14 - $27.09
Market Cap
5.1B
Average Volume 10 Days
1.4M
EPS TTM
$0.47
Shares Outstanding
113.9M
EX-Date
08/29/91
P/E TM
96.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for AKORN INC (AKRX)

akorn inc (AKRX) Related Businessweek News

No Related Businessweek News Found

akorn inc (AKRX) Details

Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment markets generic and branded ophthalmics, injectables, oral liquids, otics, topical, inhalants, and nasal sprays. This segment’s generic products include Clobetasol Propionate, a corticosteroid, which is used to treat various skin conditions; Fluticasone Propionate, a corticosteroid used for nasal symptoms of allergic and non-allergic rhinitis conditions; Lidocaine/Prilocaine, a topical anesthetic; Progesterone, which is used to prevent endometrial hyperplasia; Vancomycin, an antibiotic used to treat bacterial infections; and other products. The Consumer Health segment markets branded and private label animal health products, as well as OTC products for the treatment of dry eye under the TheraTears brand name. This segment’s branded products comprise Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; Nembutal, a sedative; and Xopenex inhalation solution for the treatment or prevention of bronchospasm. It also markets other OTC consumer health products, including Mag-Ox, a diabetes magnesium supplement, and the Zostrix brand of capsaicin products for pain management; and animal health branded and generic products comprising Anased, Tolazine, Yobine, Butorphic, and VetaKet. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

1,644 Employees
Last Reported Date: 03/17/15
Founded in 1971

akorn inc (AKRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $1.1M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $384.0K
Chief Operating Officer
Total Annual Compensation: $423.6K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $349.1K
Senior Vice President of National Accounts an...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2014.

akorn inc (AKRX) Key Developments

Akorn, Inc. Amends its Debt Agreements

Akorn, Inc. entered into (i) an ABL Consent Memorandum (the ‘ABL Consent’) in connection with its senior secured revolving credit facility made pursuant to that certain Credit Agreement, dated as of April 17, 2014, by and among the Company, as borrower, the other loan parties party thereto, Bank of America, N.A., Wells Fargo Bank, National Association, and JPMorgan Chase Bank, N.A., as lenders (the ‘ABL Lenders’) and JPMorgan Chase Bank, N.A., in its capacity as administrative agent (as amended from time to time, the ‘ABL Credit Agreement’) and (ii) a Term Loan Consent Memorandum (the ‘Term Loan Consent’, and together with the ABL Consent, the ‘Consents’) relating to its senior secured term loan facility made pursuant to that certain Loan Agreement, dated as of April 17, 2014, by and among the Company, as borrower, the other loan parties party thereto, the lenders party thereto from time to time (the ‘Term Lenders’ and, together with the ABL Lenders, the ‘Lenders’) and JPMorgan Chase Bank, N.A., as administrative agent (as amended from time to time, the ‘Term Loan Agreement’).

Akorn Gets NASDAQ Delinquency Notice For Failure To File 10-Q

Akorn, Inc. announced that it has received a notice from NASDAQ stating the Company is not in compliance with Listing Rule 5250(c)(1) for continued listing because it has not yet filed its Form 10-Q for the quarter ended March 31, 2015 by the due date of May 11, 2015. On April 24, 2015, Akorn announced that it will restate its previously issued financial statements for the annual period ending December 31, 2014 and the quarterly periods ending June 30, 2014, September 30, 2014 and December 31, 2014 due to errors identified during the first quarter 2015 financial review process. The errors will be corrected through amendments to Forms 10-Q for the fiscal quarters ended June 30, 2014 and September 30, 2014 and Form 10-K for the year ended December 31, 2014. The amended forms will be filed prior to the filing of Akorn's Form 10-Q for the fiscal quarter ended March 31, 2015. In order to maintain its listing, Akorn will submit to NASDAQ a plan of compliance by July 13, 2015 addressing any issues it believes would support its request for an extension of up to 180 calendar days from the due date of the Form 10-Q filing for the quarter ended March 31, 2015. If the plan is accepted, Akorn may be able to continue its listing during the plan period up to November 9, 2015, during which time the Company will be subject to periodic review to determine if it is making progress consistent with the plan. If the plan is not accepted, or if the Company is not in compliance by November 9, 2015, Akorn may be subject to delisting proceedings. Under NASDAQ rules, Akorn has the right to appeal any determination by NASDAQ to initiate delisting proceedings. During this process, the Company expects that its common stock will continue to be listed and traded on the NASDAQ stock market.

Akorn, Inc. announced delayed 10-Q filing

On 05/08/2015, Akorn, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKRX:US $45.20 USD +1.24

AKRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hikma Pharmaceuticals PLC 2,089 GBp -10.00
Lannett Co Inc $55.37 USD +0.05
Pacira Pharmaceuticals Inc/DE $80.08 USD +1.92
Sagent Pharmaceuticals Inc $22.56 USD -0.32
Santen Pharmaceutical Co Ltd ¥1,727 JPY -22.00
View Industry Companies
 

Industry Analysis

AKRX

Industry Average

Valuation AKRX Industry Range
Price/Earnings 100.0x
Price/Sales 8.0x
Price/Book 12.7x
Price/Cash Flow 63.3x
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AKORN INC, please visit www.akorn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.